Hidradenitis Suppurativa Market, Size, Share, Trends, Epidemiology Forecast till 2030

August 10 16:08 2020
Hidradenitis Suppurativa Market, Size, Share, Trends, Epidemiology Forecast till 2030

DelveInsight Business Research LLP
DelveInsight’s ‘Hidradenitis Suppurativa Market Insights, Epidemiology and Market Forecast-2030’ report delivers an in-depth understanding of the Hidradenitis Suppurativa, historical and forecasted epidemiology as well as the Hidradenitis Suppurativa market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom) and Japan.

Hidradenitis Suppurativa (HS) is a chronic illness characterized by swollen, painful lesions, occurring in the armpit (axillae), groin, anal, and breast regions. This disease occurs due to blockage of hair follicles and secondary infection and sometimes inflammation of certain sweat glands (apocrine glands).

 

Hidradenitis Suppurativa Epidemiology

  • The total prevalent population of Hidradenitis Suppurativa in 7MM in 2017 was 6,053,923
  • The US accounts for the highest prevalent population of Hidradenitis Suppurativa in 2017 was 2,766,042
  • Around 40% of the Hidradenitis Suppurativa patients are presented with moderate to severe symptoms at diagnosis
  • Hidradenitis Suppurativa is thrice more prevalent in females compared to males
  • The disease occurs mostly in the age groups 18─59 years.

 

Hidradenitis Suppurativa Market 

 

Hidradenitis Suppurativa Market Drivers

  • Growing Patient Pool
  • Increasing awareness of the disease
  • Improvement in healthcare economy and affordable treatment options

 

Hidradenitis Suppurativa Market Barriers

  • Diagnostic barriers
  • Treatment cost and a growing trend of complementary and alternative medicine
  • Adverse events associated with biologics

 

Scope of the Report

  • The report covers the descriptive overview of Hidradenitis Suppurativa, explaining its causes, signs and symptoms, pathophysiology and currently available therapies
  • Comprehensive insight has been provided into the Hidradenitis Suppurativa epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Hidradenitis Suppurativa are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of Hidradenitis Suppurativa market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Hidradenitis Suppurativa market

 

Hidradenitis Suppurativa Emerging Therapies

(Drug: companies logos)

  • IFX-1: InflaRx
  • Cosentyx: Novartis Pharmaceuticals
  • Avacopan: ChemoCentryx
  • Bermekimab (MABp1): xbiotech/ Janssen
  • Bimekizumab: UCB Biopharma
  • INCB054707: Incyte Corporation

 

Hidradenitis Suppurativa Marketed Drugs

  • Humira: AbbVie

 

Request for sample pages

 

Table of contents

1.   Executive Summary: Hidradenitis Suppurativa (HS)

2.   SWOT Analysis: Hidradenitis Suppurativa (HS)

3.   Hidradenitis Suppurativa (HS) Patient Share (%) Overview at a Glance

3.1.    Patient Share (%) Distribution of Hidradenitis Suppurativa in 2017 and 2030

4.   Hidradenitis Suppurativa Market Overview at a Glance

4.1.    Market Share (%) Distribution of Hidradenitis Suppurativa in 2017

4.2.    Market Share (%) Distribution of Hidradenitis Suppurativa in 2030

5.   Disease Overview: Hidradenitis Suppurativa (HS)

5.1. Introduction

5.2. Causes and Symptoms of Hidradenitis Suppurativa (HS)

5.3. Classification and Severity Assessment of Hidradenitis Suppurativa (HS)

5.3.1. Hurley Stages of HS

5.3.2. Modified Sartorius Score (MSS) of HS

5.3.3. Physician Global Assessment of Hidradenitis Suppurativa (HS-PGA)

5.3.4. Specific Severity Index of Hidradenitis Suppurativa (HSSI)

5.3.5. Pathophysiology of Hidradenitis Suppurativa

5.3.6. Genetic Basis of Hidradenitis Suppurativa (HS)

5.4. Diagnosis of Hidradenitis Suppurativa (HS)

5.4.1. Differential Diagnoses

5.4.2. Biomarkers of Hidradenitis Suppurativa (HS)

5.4.3. Risk Factors and Complications

5.4.4. Comorbidities

6.   Epidemiology and Patient Population

6.1.    Key Findings

6.2.    Assumptions and Rationale: 7MM

6.3.    Total Prevalent Patient Population of HS in the 7MM

6.4.    Total Diagnosed Prevalent Patient Population of HS in the 7MM

6.5.    Gender-Specific Prevalent Patient Population of HS in the 7MM

6.6.    Age-Specific Prevalent Patient Population of HS in the 7MM

6.7.    Stage-Specific (Severity-specific) prevalent cases of HS in the 7MM

6.8.    Treated Prevalent Cases of HS in the 7MM

7.   Country-wise Epidemiology of HS in the 7MM

7.1. United States

7.1.1. Total Diagnosed Prevalent cases of HS in the United States

7.1.2. Gender-Specific Prevalent cases of HS in the United States

7.1.3. Age-Specific Prevalent cases of HS in the United States

7.1.4. Stage-Specific Prevalent Cases of HS in the United States

7.1.5. Treated Prevalent Cases of HS in the United States

7.2. EU5

7.2.1.   Germany

7.2.1.1. Total Diagnosed Prevalent cases of HS in Germany

7.2.1.2. Gender-Specific Prevalent cases of HS in Germany

7.2.1.3. Age-Specific Prevalent cases of HS in Germany

7.2.1.4. Stage-Specific Prevalent Cases of HS in Germany

7.2.1.5. Treated Prevalent Cases of HS in Germany

7.2.2.   France

7.2.2.1. Total Diagnosed Prevalent cases of HS in France

7.2.2.2. Gender-Specific Prevalent cases of HS in France

7.2.2.3. Age-Specific Prevalent cases of HS in France

7.2.2.4. Stage-Specific Prevalent Cases of HS in France

7.2.2.5. Treated Prevalent Cases of HS in France

7.2.3.   Italy

7.2.3.1. Total Diagnosed Prevalent cases of HS in Italy

7.2.3.2. Gender-Specific Prevalent cases of HS in Italy

7.2.3.3. Age-Specific Prevalent cases of HS in Italy

7.2.3.4. Stage-Specific Prevalent Cases of HS in Italy

7.2.3.5. Treated Prevalent Cases of HS in Italy

7.2.4.   Spain

7.2.4.1. Total Diagnosed Prevalent cases of HS in Spain

7.2.4.2. Gender-Specific Prevalent cases of HS in Spain

7.2.4.3. Age-Specific Prevalent cases of HS in Spain

7.2.4.4. Stage-Specific Prevalent Cases of HS in Spain

7.2.4.5. Treated Prevalent Cases of HS in Spain

7.2.5.   United Kingdom

7.2.5.1. Total Diagnosed Prevalent cases of HS in the United Kingdom

7.2.5.2. Gender-Specific Prevalent cases of HS in the United Kingdom

7.2.5.3. Age-Specific Prevalent cases of HS in the United Kingdom

7.2.5.4. Stage-Specific Prevalent Cases of HS in the United Kingdom

7.2.5.5. Treated Prevalent Cases of HS in the United Kingdom

7.3. Japan

7.3.1. Total Diagnosed Prevalent cases of HS in Japan

7.3.2. Gender-Specific Prevalent cases of HS in Japan

7.3.3. Age-Specific Prevalent cases of HS in Japan

7.3.4. Stage-Specific Prevalent Cases of HS in Japan

7.3.5. Treated Prevalent Cases of HS in Japan

8.   Current Treatment Practices

8.1.    European S1 Guideline for the Treatment of Hidradenitis Suppurativa/Acne Inversa

8.1.1. Medical therapy

8.1.2. Surgical therapy

8.2.    North American Clinical Management Guidelines for HS

8.3.    British Association of Dermatologists guidelines for the management of Hidradenitis Suppurativa (Acne Inversa) 2018

9.      Patient Journey of Hidradenitis Suppurativa (HS)

10. Unmet Needs

11. Key Endpoints in Hidradenitis Suppurativa (HS) Clinical Trials

12. Marketed Drugs

12.1.             Humira: AbbVie

12.1.1.     Product Description

12.1.2.     Regulatory milestones

12.1.3.     Other developmental Activities

12.1.4.     Pivotal Clinical Trials

12.1.5.     Summary of Pivotal Clinical Trials

13. Emerging Therapies

13.1.             Key Cross of Emerging Therapies

13.2.             IFX-1: InflaRx

13.2.1.     Product Description

13.2.2.     Other developmental Activities

13.2.3.     Clinical Development

13.2.4.     Clinical Trials Information

13.2.5.     Safety and Efficacy

13.3.             Cosentyx (Secukinumab): Novartis Pharmaceuticals

13.3.1.     Product Description

13.3.2.     Other Developmental Activities

13.3.3.     Clinical Development

13.3.4.     Clinical Trials Information

13.3.5.     Safety and Efficacy

13.4.             INCB054707: Incyte Corporation

13.4.1.     Product Description

13.4.2.     Clinical Development

13.4.3.     Clinical Trials Information

13.5.             CJM112: Novartis Pharmaceuticals

13.5.1.     Product Description

13.5.2.     Other developmental Activities

13.5.3.     Clinical Development

13.5.4.     Clinical Trials Information

13.5.5.     Safety and Efficacy

13.6.             Bimekizumab: UCB Biopharma S.P.R.L.

13.6.1.     Product Description

13.6.2.     Other developmental Activities

13.6.3.     Clinical Development

13.6.4.     Clinical Trials Information

13.7.             Bermekimab (MABp1): Janssen Pharmaceutical

13.7.1.     Product Description

13.7.2.     Other Developmental Activities

13.7.3.     Clinical Development

13.7.4.     Clinical Trials Information

13.7.5.     Safety and Efficacy

13.8.             CFZ533 (Iscalimab) and LYS006: Novartis

13.8.1.     Product Description

13.8.2.     Other Developmental Activities

13.8.3.     Clinical Development

13.8.4.     Clinical Trials Information

13.9.             Apremilast: Celgene

13.9.1.     Product Description

13.9.2.     Clinical Development

13.9.3.     Clinical Trials Information

13.9.4.     Safety and Efficacy

13.10.          Avacopan: ChemoCentryx

13.10.1. Product Description

13.10.2. Other Developmental Activities

13.10.3. Clinical Development

13.10.4. Clinical Trials Information

13.11.          PF-06650833, PF-06700841, and PF-06826647: Pfizer

13.11.1. Product Description

13.11.2. Clinical Development

13.11.3. Clinical Trials Information

13.12.          Risankizumab: AbbVie

13.12.1. Product Description

13.12.2. Clinical Development

13.12.3. Clinical Trials Information

13.13.          Guselkumab: Janssen Pharmaceutical

13.13.1. Product Description

13.13.2. Other Developmental Activities

13.13.3. Clinical Development

13.13.4. Clinical Trials Information

14. Attribute Analysis of Hidradenitis Suppurativa (HS) Therapies

15. Hidradenitis Suppurativa (HS): 7 Major Market Analysis

15.1. Key Findings

15.2. Market Size of Hidradenitis Suppurativa in 7MM

15.3. Market Size by therapies of Hidradenitis Suppurativa in 7MM

16. Market Outlook: 7MM

16.1.             United States Market Size

16.1.1.     Total Market size of Hidradenitis Suppurativa

16.1.2.     Hidradenitis Suppurativa Market by Therapies

17. EU-5 Countries

17.1.             Germany Market Size

17.1.1.     Total Market size of Hidradenitis Suppurativa

17.1.2.     Hidradenitis Suppurativa Market by Therapies

17.2.             France Market Size

17.2.1.     Total Market size of Hidradenitis Suppurativa

17.2.2.     Hidradenitis Suppurativa Market by Therapies

17.3.             Italy Market Size

17.3.1.     Total Market size of Hidradenitis Suppurativa

17.3.2.     Hidradenitis Suppurativa Market by Therapies

17.4.             Spain Market Size

17.4.1.     Total Market size of Hidradenitis Suppurativa

17.4.2.     Hidradenitis Suppurativa Market by Therapies

17.5.             United Kingdom Market Size

17.5.1.     Total Market size of Hidradenitis Suppurativa

17.5.2.     Hidradenitis Suppurativa Market by Therapies

18. Japan

18.1. Total Market size of Hidradenitis Suppurativa

18.2. Hidradenitis Suppurativa Market by Therapies

19. Market Access and Reimbursement Scenario of Hidradenitis Suppurativa (HS) Therapies      

20. Market Drivers

21. Market Barriers

22. Appendix

22.1. Bibliography

22.2. Report Methodology

23. Disclaimer

24. DelveInsight Capabilities

25. About DelveInsight

Media Contact
Company Name: DelveInsight
Contact Person: Priya Maurya
Email: Send Email
Phone: +919650213330
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/


Warning: count(): Parameter must be an array or an object that implements Countable in /home/haridwartoday/goaheadlines.org/wp-content/themes/gadgetine-theme/includes/single/post-tags-categories.php on line 7